observed resulting in both significant reduction of tumor load and decreased tumor vasculature. These results suggest the potential for anti-EMP2 IgG1 as a promising novel anti-angiogenic therapy for GBM. Further investigation is needed to fully understand the molecular mechanisms how EMP2 modulates GBM pathogenesis and progression and to further characterize anti-EMP2 therapy in GBM.
Introduction
Glioblastoma multiforme (GBM) is the most common, aggressive malignant brain tumor, affecting 3.2 per 100,000 adults each year in the USA. GBMs often present in patients as de novo grade IV astrocytoma and less frequently present as a lower grade (I-III) tumor [1] . The etiology of GBM is poorly understood and the standardof-care treatment involves maximal surgical resection followed by radiation and chemotherapy with temozolomide [2] . Despite the multimodality treatment, the clinical outcome of GBM patients is extremely poor with a median survival of 12 months and a 5-year survival of <10% [1] . Two features of GBM present significant treatment challenges: (1) GBM is highly invasive which makes complete surgical resection almost impossible; (2) GBM is highly vascularized with abnormal vessels that appear disorganized, are large in diameter with thick basement membrane, and have low levels of pericytes [3] . The endothelial cells from patients with GBM are distinct and carry the same somatic mutations suggesting tumor endothelial cells originate from GBM peritumor niche [4, 5] . While all the factors regulating angiogenesis in GBM are not known, one growth factor implicated in promoting GBM malignancy is vascular endothelial growth factor A (VEGF-A) [6] . Bevacizumab, a monoclonal antibody targeting VEGF-A, is currently a first-line treatment for recurrent GBM and shows a progression free survival benefit. However, there is no clear overall survival benefit [7, 8] . Thus, a better understanding of GBM vasculature as well as novel anti-angiogenic therapy in GBM is urgently needed.
Epithelial membrane protein-2 (EMP2) is a member of the growth arrest specific-3 (GAS-3) family of tetraspan proteins. Previously we reported that EMP2 is present in most human GBM biopsies and undetectable in normal human brain tissues [9] . Furthermore, high EMP2 levels are associated with poor survival rates implicating it as an important prognostic and diagnostic marker. Mechanistically, EMP2 promotes GBM invasive phenotype in part through activating integrin-FAK-Src signaling [9] . In this study, we further examine the effect of EMP2 expression levels on GBM pathogenesis as well as the therapeutic benefit of anti-EMP2 IgG1 therapy. We demonstrate that EMP2 levels promote GBM neoangiogenesis partially through increasing VEGF-A levels. We also show that anti-EMP2 IgG1 antibody therapy dramatically reduce intracranial GBM tumor load and vasculature formation in tumor tissues. These results strongly support the utilization of EMP2-targeting therapy as an alternative anti-angiogenic therapy for GBM patients.
Materials and methods

Cell lines and reagents
Human GBM cell lines T98, U118 or U87MG (ATCC, Manassas, VA) were cultured in DMEM supplemented with 10% fetal bovine serum (Hyclone Cat#30071), 1% glutamine, 1% penicillin and streptomycin, and 1% sodium pyruvate in a humidified 5% CO 2 incubator at 37 °C. EMP2 expression was stably overexpressed or reduced using methods previously described [9] . Briefly, EMP2 was stably overexpressed using a retroviral vector encoding EMP2 and green fluorescent protein (GFP) or EMP2-GFP fusion protein. EMP2 expression was reduced using a lentiviral vector or an EMP2-specific ribozyme (RIBO), and for these cell lines an appropriate plasmid or shRNA vector control (CTRL) was used [9] . To create intracranial tumors, U87MG/EMP2, U87MG/CTRL and U87MG/shRNA were stably infected with a lentiviral vector containing firefly luciferase reporter gene (Luc) by the UCLA CURE Vector Core Facility. Cells were used within 2 months after resuscitation of frozen aliquots and were authenticated by the supplier. Cells were passaged every 2-4 days. Human umbilical vein endothelial cells (HUVEC; ATCC) were cultured in VTEC media as per manufacturer's instructions (Lonza, Allendale, NJ) and were used within the first 10 cell passages.
Intracranial U87MG tumor implantation
All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health. The protocol was approved by the Office of Animal Research Oversight at UCLA. All efforts were made to minimize animal suffering. To create intracranial tumors, U87MG/ EMP2/ Luc (n = 6 mice), U87MG/CTRL/Luc (n = 11 mice), or U87MG/shRNA/Luc cells (n = 12 mice) were stereotactically implanted into the right frontal lobe of 6-8-weekold female BALB/c athymic nude mice (Jackson Laboratory, Bar Harbor, ME) under adequate anesthesia. Specifically, tumor cells (1 × 10 5 in 2 μl sterile PBS for each mouse) were injected 2.8 mm deep into right frontal lobe using a 26-gauge Hamilton syringe, 1 mm anterior and 1.5 mm lateral relative to the intersection of the coronal and sagittal sutures on the skull. Animal health was monitored for the behavioral and neurological abnormalities as well as weight loss. Tumor burden was monitored by bioluminescence imaging using IVIS 200 as previously described [9] . Images were captured from day 1 to day 21 and day 18 imaging post tumor implantation was analyzed. This experiment was performed with six animals per group. To ensure the reproducibility of the
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results between the control and knockdown groups, a second experiment with another six animals was performed. The results from the first and second experiments were combined with one animal excluded due to over-inhalation of isoflurane during imaging.
To determine the anti-EMP2 IgG1 therapeutic effect, the EMP2-overexpressing cell line U87MG/EMP2/Luc cells (1 × 10 5 cells per 2 μl sterile PBS for each mouse) were stereotactically implanted into the right frontal lobe of 6-8-week-old female athymic nude mice under adequate anesthesia as described above. We have previously described the creation of an anti-EMP2 IgG1 antibody [10] . To ensure consistency among experiments, anti-EMP2 IgG1 was prepared in bulk by Lake Pharma on a contractual basis according to their standard practices. Each antibody preparation includes a certificate of analysis ensuring the size, purity, and affinity of the antibody.
From day 1, mice were intraperitoneally injected with either control vehicle (n = 5 mice) or anti-EMP2 fulllength IgG1 antibody (n = 6 mice) twice a week for 3 weeks. This first three anti-EMP2 antibody treatments were administered as 10 mg/kg body weight of mouse and last three anti-EMP2 treatments were 20 mg/kg body weight of mouse. Bioluminescence images were captured on days 1, 7, 14 and 21 post tumors implantation to monitor tumor growth. A two-way analysis of variance was used to determine the difference between control and anti-EMP2 IgG1 antibody treatment groups within treatment time course. Significance was defined as *p < 0.05, **p < 0.001, ***p < 0.0001.
Affymetrix RNA microarray
RNA was extracted from cells that were genetically altered to change EMP2 expression levels. U118/EMP2, U118/ CTRL or U118/shRNA cell lines were extracted using the Qiagen RNA isolation kits as per manufacturer's instruction (Qiagen Inc, Valencia, CA). Affymetrix U133 plus 2.0 microarray (Affymetrix, Santa Clara, CA) was performed in duplicate by UCLA Clinical Microarray Core Facility. Briefly, each RNA sample quality was validated by measuring absorbance 260/280, and samples in the range of 1.8-2.1 of 260/280 ratio were used for cDNA. RNA was converted to cDNA, hybridized onto microarray chips, followed by stringent washing and subsequent labeling with probes for automated visualization. An average of duplicate samples was taken and the relative abundance of specific gene expression was determined among groups. A heat map was created with R software (http://www.r-project. org) to identify differences and pathway analysis was created with Ingenuity software (http://www.ingenuity.com) by the UCLA Clinical Microarray Core Facility.
Immunohistochemistry
After euthanization, mouse brains were harvested and fixed in 10% formalin for 72 h. Coronal cross sections of brain tumors were cut along the implant sites to expose tumors, followed by paraffin embedding. Tumor tissues were stained for CD34 to visualize endothelial cells [11] . Briefly, for antigen retrieval, sections were incubated at 95 °C for 20 min in 0.1 M citrate buffer, pH 6. CD34 was detected using rabbit anti-human CD34 (Abcam, cat#81289) at a dilution of 1:100 at 4 °C overnight followed by visualization using the Vector ABC kit (Vector Labs, Burlingame, CA). Tumor sections were also stained with Masson's trichrome in order to visualize the collagen fibers within tumor tissues as per manufacturer's instruction (Polysciences Inc., Warminster, PA).
Image analysis of CD34 staining
CD34 staining of tumor tissues was analyzed with Image J software with a custom macro script. Specifically, images of CD34 stained vascular endothelia were captured in RGB format under ×400 magnification and a 1360 × 1024 resolution using an Olympus BX51 microscope with a DP72 camera (Olympus Inc., Japan). Images were analyzed using the Fiji distribution of NIH ImageJ [12, 13] . The blue channel had the best contrast ratio and was used for all subsequent image analysis steps. Images were segmented by thresholding intensity values using Otsu's method [14] . Objects in the resulting binary mask were closed using two passes of dilation followed by two erosions. Any remaining small objects and salt-and-pepper noise were removed using two erosions followed by two dilations. Masked objects were used to measure the area of the original blue channel information. The results were tabulated to compared the difference among groups.
HUVEC migration
× 10
5 T98, U118, U87MG cells that were genetically modified to vary in EMP2 expression were cultured in 6-well plates for 48 h. Conditioned media were collected at the end of incubation. To determine the biologic effects of cell-secreted angiogenic factors into the conditioned media, 1 × 10 4 HUVEC cells were plated in the top chamber inserts of 24-well transwell (Corning Costar, Tewksbury, MA) and conditioned media from the cells were added into the bottom wells and the co-culture was incubated at 37 °C for 5 h. The filters of inserts were fixed with 3.7% formaldehyde at room temperature for 10 min and followed by staining with 0.1% crystal violet in 20% methanol at room temperature for 10 min. The migrated HUVEC cells were visualized using bright field microscopy. Migratory cell numbers 1 3
were averaged by counting four random fields per transwell under ×400 magnification. The experiment was repeated at least three times.
To determine the effect of the anti-EMP2 IgG1 antibody on cell-secreted angiogenic factors, 2.5 × 10 5 U87MG wild type cells were cultured in 6-well plates in the presence of 50 μg/ml anti-EMP2 full-length IgG1 antibody (n = 4) or a vehicle control (n = 3) for 48 h. Conditioned media were collected at the end of incubation. HUVEC migration assay was performed as described above.
HUVEC tube formation
Conditioned media were collected as noted above from panels of T98, U118, and U87MG cells with varied EMP2 expression levels. Cover slips were placed in 24-well plates and coated with freshly thawed cold Geltrex LDEV-free reduced growth factor basement membrane matrix (ThermoFisher, Waltham, MA) diluted with ice cold PBS (1:1, vol/vol). Geltrex-coated cover slips were solidified at 37 °C for 30 min and excess liquid was removed. 1 × 10 5 HUVEC cells were mixed in 500 μl conditioned media and added onto Geltrex-coated cover slips. Cells were incubated at 37 °C for 16 h. To visualize HUVEC cells, 4 μg/ ml calcein (ThermoFisher) was added into cells at 37 °C for additional 30 min. Tube formation was evaluated under a fluorescent microscope (Olympus BX51) and the number of fully formed capillary tubes were counted on the entire cover slips. The experiment was performed in triplicate and repeated at least three times.
SDS-PAGE/Western blots
Cells were lysed in Laemmle sample buffer (62.5 mM Tris-Cl, pH 6.8, 10% glycerol, 2% SDS, 0.01% bromphenol blue, 2% β-mercaptoethanol). For detection of EMP2, lysates were de-glycosylated as described previously [9] . Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes (Amersham Biosciences, Pittsburg, PA). Membranes were blocked with 5-10% low fat milk in TBS containing 0.1% Tween-20 and probed with polyclonal anti-EMP2 antibody 1:2000, anti-VEGF-A 1:200 (Santa Cruz Biotechnology, clone A-20, sc-152, Dallas, TX) and anti-β-actin 1:10,000 (Sigma, A2228, St Louis, MO), anti-phospho-STAT3 1:1000 (Cell Signaling, #9145, Danvers, MA), anti-STAT3 1:3000 (Cell Signaling, #4904, Danvers, MA), followed by HRP-conjugated secondary antibodies (Southern Biotechnology Associates, Birmingham, AL). Protein bands were visualized by chemiluminescence (Amersham Biosciences, Pittsburg, PA) and band intensities were quantified using NIH Image J software. All experiments were performed at least three times.
VEGF-A ELISA
To determine the cell-secreted VEGF-A levels, 2.5 × 10 5 T98, U118 or U87MG cells with varying EMP2 expressions were cultured in 6-well plates for 48 h. Conditioned media were collected at the end of incubation. Secreted VEGF-A levels in conditioned media were examined with human VEGF Quantikine ELISA kit (DVE00, R&D Systems Inc., Minneapolis, MN) as per manufacturer's instruction. Briefly, conditioned media were added into 96-well anti-VEGF antibody coated-plates at room temperature for 2 h. Following stringent washing three times, the samples were incubated with conjugated-VEGF antibody at room temperature for 2 h. Following washing three times, substrates were added and VEGF-A levels were quantified in comparison with a standard curve using a SpectraMax 190 microplate reader (Molecular Devices, Sunnyvale, CA). To determine the effect of the anti-EMP2 IgG1 antibody on cell-secreted VEGF-A levels, 2.5 × 10 5 U87MG wild type cells were cultured in 6-well plates in the presence of 50 μg/ml anti-EMP2 full-length IgG1 antibody (n = 4) or a vehicle control (n = 3) for 48 h. Conditioned media were collected at the end of incubation. VEGF-A ELISA was performed as noted above. Experiments were performed in duplicate and repeated three times.
Statistical analysis
All values in the text are represented as the mean ± standard error of the mean (SE). Differences between means were determined using a one-way, two-way analysis of variance or student's t test as indicated in the figure legends or text. Significance in all cases was defined as *p < 0.05, **p < 0.001, ***p < 0.0001.
Results
EMP2 promotes GBM angiogenesis in intracranial U87MG tumors
We previously showed that EMP2 overexpression promoted a more invasive phenotype while tumors with reduced levels of EMP2 produced smaller, less invasive tumors [9] . To extend this work, the vasculature of intracranial tumors derived from U87MG cells expressing different levels of EMP2 was examined. EMP2 expression was validated by Western blots prior to intracranial tumor implantation and increased (6 fold) or reduced (10 fold) EMP2 levels compared with control cells were stable during the experiments (Fig. 1a) . Consistent with previous findings, on day 18 post tumor implantation, reduction of EMP2 by shRNA (U87MG/shRNA) significantly decreased intracranial U87MG tumor growth compared to control scrambled shRNA (U87MG/CTRL). However, overexpression of EMP2 (U87MG/EMP2) did not increase the tumor mass based on bioluminescence imaging (Fig. 1b) .
Histological examination of the tumors suggested differences in tumor-associated vasculature. In order to confirm these effects, brain tumor sections were stained with CD34, a marker of endothelial cells. The CD34 staining revealed a striking difference among groups with more and larger blood vessels formed in U87MG/EMP2 and fewer, smaller blood vessels in U87MG/shRNA compared with U87MG/CTRL intracranial tumors (Fig. 1c, left) .
Automated quantification using NIH Image J with a custom macro script for CD34 staining confirmed that U87MG/ EMP2 tumors had significantly higher levels of CD34 staining compared to U87MG/CTRL and U87MG/shRNA (Fig. 1d) . Concordantly, tumor sections were stained with Masson's trichrome to differentiate tumors from surrounding connective collagen tissues and the results confirmed more collagen tissues (in blue) in U87MG/EMP2 and less in U87MG/shRNA compared with U87MG/CTRL tumors (Fig. 1c, right) . These data collectively suggest that EMP2 plays an important role in promoting angiogenesis and regulating tumor vasculature in GBM tumors in vivo. 
EMP2-regulated angiogenic factors potentiate HUVEC migration and capillary tube formation in vitro
To characterize the effects of EMP2 on angiogenesis in GBM cell lines, in vitro endothelial cell functional assays were performed using panels of T98, U118 and U87MG cells which expressed different levels of EMP2 and have been previously described [9] . Conditioned media from panels of T98, U118 and U87MG revealed a significant positive correlation between EMP2 levels and HUVEC cell migration using a Boyden-chamber transwell migration assay (Fig. 2a) . To confirm and extend these results, the ability of EMP2 to promote capillary tube formation in vitro was determined. In two of the three cell lines, T98 and U118, conditioned media from cells with higher EMP2 levels enhanced capillary tube formation compared with the ones from control cells. In contrast to the other cell lines, under normoxic conditions, U87MG cells effectively formed endothelial tubes independent of EMP2 expression (Fig. 2b) . These results suggested that EMP2 levels promote endothelial recruitment and in some cases can promote more efficient tube formation.
EMP2 increases VEGF-A expression and secretion in GBM cells
Several pathways have been implicated in the regulation of angiogenesis in GBM. The best characterized angiogenic factor is VEGF-A, which has been shown to be indispensable for organ development as well as for growth in a number of tumors [15] . Given the evidence that EMP2 regulates endothelial cell migration and the critical role of VEGF-A in GBM, its expression was characterized in tumor cells with different levels of EMP2. Expression of VEGF-A was quantitated from panels of T98, U118 and U87MG normalized to β-actin (Fig. 2c) and cell-secreted VEGF-A levels were determined by ELISA (Fig. 2d) . In all three cell lines, reduction in EMP2 by either ribozyme or shRNA produced a concomitant reduction in VEGF-A. Increased EMP2 appeared to directly upregulate VEGF-A in T98 cells but this effect was not statistically significant in U118 or U87MG (Fig. 2c, d ). These results suggest that EMP2 expression is required for VEGF-A production but perhaps there is a threshold beyond EMP2 cannot augment its translation. This also suggests that the increase in endothelial cell migration by increased EMP2 may be independent of VEGF-A.
U118 Affymetrix RNA microarray
A number of pathways have been shown to modulate neoangiogenesis in GBM [16, 17] . In order to characterize the transcriptional changes induced by modulating EMP2 levels, transcriptome profiling was performed using the Affymetrix U133 plus 2.0 Microarray. U118 cells were selected as EMP2 levels regulated both endothelial cell migration and capillary tube formation in this cell line. RNA from U118/EMP2, U118/CTRL or U118/shRNA was analyzed for comparison among groups for differential gene expression. The Venn diagram detailed gene expression between groups (Fig. 3a) . Among which 129 genes were expressed more than 1.5 fold between groups and 71 genes showed a reciprocal regulation between the three cell lines (Sup 1). Heat map analysis of these 129 genes displayed the differential gene profiling hierarchy among the three groups (Fig. 3b) . In addition, we performed the pathway analysis using Ingenuity software and identified 217 pathways that were associated with high EMP2 gene levels (EMP2 vs. CTRL, Sup 2).
EMP2 regulates STAT3 in some GBM cells
In order to focus on the role of EMP2 in neoangiogenesis, pathways linked to GBM neoangiogenesis were further validated. Signal transducer and activator of transcription 3 (STAT3) is a transcriptional factor that modulates a diverse set of cellular functions including neoangiogenesis. Moreover, STAT3 activity has recently been implicated in driving GBM pathogenesis [18] . In order to validate and extend the regulation of STAT3 by EMP2, lysates were prepared as above from three GBM cell lines. STAT3 activation was determined by measuring its phosphorylation at tyrosine 705 normalized by total STAT3. The results showed Fig. 3 U118 Affymetrix RNA microarray and EMP2 regulates STAT3 in some GBM cells. RNA was extracted from U118/EMP2, U118/CTRL or U118/shRNA. Affymetrix U133 plus 2.0 microarrays were performed in duplicate and the average of two samples was taken. The relative abundance of specific gene expression was determined among groups. a Gene expression was detailed between groups in a Venn diagram. b 129 genes were expressed more than 1.5 fold between groups and heat map analysis displayed the differential gene profiling hierarchy among three groups using R software. c T98, U118 or U87MG cells with different levels of EMP2 were cultured for 48 h and cells were lysed to evaluate total STAT3 expression as well as STAT3 phosphorylation at Y705 by Western blots. Quantification of STAT3 phosphorylation normalized by total STAT3 expression were determined by NIH Image J software (top) and representative images of Western blots showed the expression of p-STAT3, STAT3 or β-actin (bottom). The experiments were repeated at least three times. One-way analysis of variance with a Bonferroni post-test was calculated to determine the difference among three groups. Significance was defined as **p < 0.001, ***p < 0.0001
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heterogeneity among GBM cell lines. In panels of T98 and U118 cells, overexpression of EMP2 increased activated STAT3 whereas reduction of EMP2 reduced its activation compared with control cells. However, in contrast to the other two cell lines, there was no effect of EMP2 on STAT3 activation observed in panel of U87MG cells (Fig. 3c) . These results suggest that neoangiogenic signaling can be regulated by multiple pathways and may reflect the heterogeneity between different GBM cell lines.
Anti-EMP2 reduces intracranial U87MG/EMP2 tumor load and angiogenesis
Our group have previously developed and characterized a humanized monoclonal anti-EMP2 IgG1 and examined its therapeutic effect in multiple model systems [9, 10] . To further determine the application of this monoclonal antibody treatment in GBM, we established intracranial murine models using the more aggressive U87MG/EMP2 tumors. Tumor growth was monitored by bioluminescence imaging on day 1, 7, 14 and 21 post tumor implantation. Systemic anti-EMP2 IgG1 antibody treatment was initiated from day 1 post implantation. At day 14 and 21 we observed a significant reduction of tumor load from anti-EMP2 IgG1-treated animals compared to control vehicle-treated animals (Fig. 4a) . At day 21, intracranial tumors were collected and the gross histology and vasculature was assessed. Hematoxylin and eosin staining showed similar invasion along the margins of the tumor (Fig. 4b, left b Representative histological images (left, top) and CD34 staining (left, bottom) of intracranial tumors from two groups were displayed under ×40 and ×200 magnification, respectively, and staining was automated quantification using NIH Image J software with a custom macro script were examined (right). Student's t test was used to determine the difference between the two groups. Significance defined as *p < 0.05, ***p < 0.0001 CD34 staining revealed a robust reduction in angiogenesis in anti-EMP2 IgG1-treated animals compared to the vehicle control-treated ones (Fig. 4b, left bottom) . Automated quantification of CD34 staining showed a 68.1% reduction in CD34 staining area in anti-EMP2 IgG1-treated mice compared with control vehicle-treated mice (Fig. 4b, right) . These results suggest that anti-EMP2 IgG1 may be a novel anti-angiogenic therapy for GBM in this model system. To further elucidate the mechanism of the antibody, U87MG cells were treated with the anti-EMP2 IgG1 antibody or a vehicle control and conditioned media were collected. HUVEC migration assay demonstrated a significant reduction in HUVEC cell recruitment in the presence of anti-EMP2 antibody compared with vehicle control (Fig. 5a ). Concordantly, VEGF-A expression in tumor cells (Fig. 5b) and cell-secreted VEGF-A levels in conditioned media (Fig. 5c) were also significantly decreased by treatment of anti-EMP2 IgG1 antibody compared with vehicle control. Both in vivo and in vitro studies demonstrated a promising therapeutic effect of anti-EMP2 IgG1 antibody in these GBM models that resulted in smaller tumor sizes and fewer tumor vasculatures.
Discussion
Despite numerous efforts in the research of GBM pathogenesis and multimodality treatment, the prognosis of GBM patients is still very poor [1] . In this report we demonstrate that EMP2 may be a promising therapeutic target due to its high specificity in GBM tumors and its effect in regulating multiple downstream targets including neoangiogenesis. EMP2 is present in over 90% GBM patient samples from human brain tumor tissue microarray but is absent in normal brain, suggesting its utility as a therapeutic and/or diagnostic target for the disease [9] . GBM tumors exhibit 
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50µm two classical hallmarks. They are typically highly invasive into surrounding brain parenchyma as well as excessive vascularization with abnormal blood vessels which appear disorganized, large in diameter with thick basement membrane and low levels of pericytes. Concordantly, high EMP2 levels in GBM are associated with a more invasive phenotype, and an increase in EMP2 by genetic engineering dramatically increased tumor invasion [9] . In this report, we further demonstrate that engineered, high EMP2 levels are associated with both an increase in number as well as size of blood vessels in GBM tumors. The effect of altered EMP2 levels on endothelial cells can be recapitulated in vitro as cell lines with higher EMP2 levels recruit more endothelial cells and in some cell lines is sufficient to induce neovascularization. This regulatory effect is in part due to upregulation of VEGF-A levels. Anti-angiogenic therapies are currently in use as second line therapies for GBM. The FDA granted accelerated approval to bevacizumab as a single agent for patients with progressive disease, and although it results in a progression-free survival benefit, it does not alter overall survival for patients with GBM. Recurrence for these patients has been associated with poor tumor oxygenation with the resulting bevacizumab resistant glioblastomas showing increased c-Met, focal adhesion kinase, and STAT3 phosphorylation [19] [20] [21] . In contrast to the anti-angiogenics on the market, anti-EMP2 therapy alters the tumor cell. Our group has previously developed and characterized a humanized monoclonal IgG1 antibody targeting EMP2 [10] , and we examined its therapeutic effect using intracranial U87MG/EMP2 tumor xenografts. We find the systemic treatments using anti-EMP2 antibody significantly reduced tumor load by bioluminescence imaging and formed less vasculature in tumor tissues, suggesting it may be a promising novel anti-angiogenic therapy for GBM.
Using Affymetrix RNA microarray technology, modulation of EMP2 levels altered several signaling pathways. In this report, we focus on the pathways previously implicated in regulating neoangiogenesis. STAT3 activation regulates diverse cellular functions including neoangiogenesis. Persistent STAT3 phosphorylation is detectable in 70% of human tumors and in up to 83% of primary GBM [18] . JSI-124, a natural chemical compound and a potent STAT3 inhibitor, effectively inhibits VEGF-A expression, prevents HUVEC migration and capillary tube formation and also reduces invasiveness of GBM cells [22] . In our study, EMP2 increased STAT3 phosphorylation in T98 and U118 but not in U87MG panels, and we predict this discrepancy is likely due to the heterogeneity of molecular backgrounds of GBM cell lines. It is well established that GBM cell lines are highly heterogeneous, and this can include alterations in p53 and/or PTEN. Tumor suppressor p53 mutation is very common in GBM and seen in 25-30% of primary GBM and 60-70% of secondary GBM [23] . Phosphatase and tensin homolog (PTEN) mutations are observed in up to 40% of GBM tumors, and dual inactivation of p53 and PTEN in murine neural stem cells promotes undifferentiated tumors [24] . It is known, for example, that U87MG has a mutant PTEN but wild type p53 and is classified as an epithelial cell line. In contrast, U118 has both mutant PTEN and p53 and is characterized as mixed cell line, while T98 is typically characterized as a p53 mutant mesenchymal cell [25] [26] [27] . In this context, it has been shown that STAT3 can have varying effects based on PTEN status, where it can act as a tumor suppressor in some GBM cell lines with PTEN deficiency [28] . We thus predict that signaling from EMP2, a membrane protein, is upstream of these mutations, but its effect on STAT3 signaling can become more or less dominant depending on the other alterations within the cell. Likewise, the downregulation of EMP2 by the antibody inhibits tumor associated VEGF-A production with one direct effect being a decrease in VEGF secretion.
Drug delivery is one of the major formidable obstacles in treating GBM and standard systemically administered chemotherapy is often insufficient to deliver across intact blood brain barrier (BBB). The homeostasis of BBB is essential for normal brain functions. Detailed mechanisms of BBB are still elusive, but it is formed by the tight junctions of brain capillary endothelial cells surrounded by astrocytes, pericytes and microglial [29] . The intact BBB prevents passage of water-soluble compounds with a molecular weight >180 Da; however, most chemotherapeutic agents have molecular weight >200 Da [30] . In GBM, the BBB is compromised and leaky which leads to edematous swelling, increased intracerebral pressure, and possible passage of compounds with a greater molecular weight [29] . In this study, we predict that the anti-EMP2 IgG1 antibody may successfully cross the leaky BBB in a compromised state.
In conclusion, our study revealed a novel role for EMP2 in regulating GBM tumor-stromal interactions. EMP2 in the tumor promoted endothelial recruitment and vessel formation, and this effect could be recapitulated in vivo. We further show that anti-EMP2 IgG1 antibody therapy may be a novel anti-angiogenic treatment for GBM through a decrease in tumor-associated VEGF-A. Additional studies are needed to further translate the effects of the anti-EMP2 IgG1 to further explore how timing, dose, and other delivery methods (intratumor, intrathecal vs. systemic) may improve its utility.
